Autolus Therapeutics plc (AUTL) stock
AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3019% below fair value
$1.14−0.03 (-2.56%)
Close on Nov 16, 2026Market cap $303.43MP/E –Yield –
Autolus Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Autolus Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was -210.8%. For fiscal 2025 it was -358.9%, against -2385.6% the year before. The highest annual figure on record is -358.9% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -358.9% | +2026.8 |
| FY2024 | Dec 31, 2024 | -2385.6% | +8197.5 |
| FY2023 | Dec 31, 2023 | -10583.1% | −6494.0 |
| FY2018 | Sep 30, 2018 | -4089.1% | −2705.8 |
| FY2017 | Sep 30, 2017 | -1383.2% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | -95.9% | +196.6 |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -227.0% | +499.3 |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | -298.3% | +261301.7 |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -337.9% | +46.1 |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -292.6% | +14529.7 |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -726.3% | +12769.9 |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -261600.0% | −250190.8 |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -384.1% | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -14822.3% | – |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | -13496.2% | – |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | -11409.2% | – |
See a number that looks wrong?